By Dr. Moxit Shah, DM Endocrinologist
Vishuddha Endocrine Clinic, Ahmedabad
GLP-1 medicines have become an important part of modern treatment for type 2 diabetes and obesity. At the same time, a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) has received increasing attention, particularly in relation to semaglutide.
Patients understandably ask: Can GLP-1 medicines cause sudden vision loss? Should semaglutide be stopped? Does the same concern apply to tirzepatide?
The answer in 2026 is nuanced. Regulatory authorities have recognized NAION as a very rare adverse effect of semaglutide, while observational studies have produced mixed estimates of risk and cannot by themselves prove causation. Evidence for a class-wide GLP-1 effect, and particularly for tirzepatide, remains less certain.
What is NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It occurs when the blood supply to the front portion of the optic nerve is disrupted, resulting in sudden optic-nerve dysfunction.
Typical NAION presents as sudden, usually painless loss or reduction of vision in one eye. Some people notice the problem on waking. The visual deficit can be permanent, so sudden visual loss requires prompt ophthalmological assessment.
Why has GLP-1 and NAION become a concern?
The concern emerged from observational research reporting more NAION diagnoses among some patients receiving GLP-1 receptor agonists, especially semaglutide.
However, people who receive GLP-1 medicines frequently have diabetes, obesity, hypertension, sleep apnea and other vascular risk factors. Several of these conditions are independently associated with NAION. This makes it difficult to determine whether an observed association is caused by the medicine itself or partly by differences between treated and untreated populations.
What is the current regulatory position on semaglutide?
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee concluded in 2025 that NAION is a very rare side effect of semaglutide. EMA reported that several large epidemiological studies suggested approximately a two-fold relative increase in NAION among adults with type 2 diabetes exposed to semaglutide, corresponding to approximately one additional case per 10,000 person-years.
The EMA recommends that patients taking semaglutide who develop sudden loss of vision or rapidly worsening eyesight seek medical attention without delay. If NAION is confirmed, semaglutide treatment should be discontinued.
Read the EMA safety communication.
What does the 2026 evidence show?
A 2026 study published in Diabetes Care evaluated adults with type 2 diabetes who newly started a GLP-1 receptor agonist compared with people who newly started a DPP-4 inhibitor.
At one year, NAION occurred in:
- 18.5 per 100,000 GLP-1 RA initiators
- 7.2 per 100,000 DPP-4 inhibitor initiators
The adjusted relative risk was 2.56 (95% CI 1.44–4.86), with an absolute risk difference of 11.3 per 100,000 at one year. The association was stronger during the first six months of treatment and varied across patient subgroups.
Importantly, this was an observational study. It demonstrates an association, not definitive proof that GLP-1 medicines caused NAION.
Read the 2026 Diabetes Care study.
What do systematic reviews and meta-analyses say?
The evidence is not completely uniform.
A 2026 systematic review and meta-analysis found an association between semaglutide and NAION compared with non-GLP-1 treatments. Another 2026 systematic review emphasized that the evidence remains uncertain and that confounding by diabetes, obesity and cardiovascular disease may influence the observed association.
This difference between analyses is important: the existence of a statistical association does not automatically establish a causal drug effect.
Further prospective research with standardized ophthalmic diagnosis is needed to determine the true magnitude of risk.
How big is the risk?
This is where patients should distinguish relative risk from absolute risk.
A study may report a two-fold or greater relative increase, but NAION itself is rare. EMA’s assessment estimated approximately one additional case per 10,000 person-years of semaglutide exposure.
Therefore, the current evidence does not suggest that most people taking semaglutide will develop NAION.
Does the concern apply to all GLP-1 medicines?
Not necessarily.
The strongest regulatory safety signal has been associated with semaglutide. The World Health Organization’s safety committee has stated that the NAION signal is driven primarily by semaglutide data and that a class effect across all GLP-1 receptor agonists cannot yet be determined.
For other GLP-1 receptor agonists, evidence is less consistent. Individual medicines should therefore not automatically be treated as having identical risk.
What about tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It is not simply another semaglutide formulation.
At present, there is not enough evidence to conclude that tirzepatide carries the same NAION risk signal established for semaglutide. This should not be interpreted as proof that the risk is zero; rather, the evidence is currently insufficient to establish the same association.
Who may already be at higher risk of NAION?
NAION has recognized associations with several vascular and anatomical factors, including:
- Diabetes
- Hypertension
- Obstructive sleep apnea
- Smoking
- Dyslipidemia
- Older age
- Certain optic-disc anatomical features
This is particularly relevant because many people prescribed GLP-1 medicines have one or more of these risk factors.
What symptoms should GLP-1 patients watch for?
The most important warning symptom is:
Sudden, painless reduction or loss of vision in one eye.
Patients may describe:
- Sudden blurred vision
- A missing area of the visual field
- Dimness in one eye
- Sudden visual change noticed after waking
Do not wait for a routine appointment if this happens. Seek urgent ophthalmological or emergency medical assessment.
Should you stop Ozempic or semaglutide if you have blurred vision?
Not every visual symptom is NAION. Blurred vision can have many causes, including changes in blood glucose, refractive problems, diabetic retinopathy and other eye conditions.
However, sudden or rapidly worsening vision requires urgent assessment.
If NAION is confirmed in a patient taking semaglutide, the EMA product information recommends discontinuing semaglutide. This decision should be made in the context of the confirmed diagnosis and the patient’s overall diabetes or obesity treatment plan.
Do all GLP-1 patients need a special eye examination?
There is currently no general recommendation that every person starting a GLP-1 medicine undergo a special NAION screening examination solely because of the medication.
People with diabetes should continue recommended diabetic eye screening. Patients with known optic-nerve disease, significant eye disease or new visual symptoms may need individualized ophthalmological evaluation.
What does the ADA say in 2026?
The ADA Standards of Care in Diabetes—2026 list NAION as a rare reported adverse event associated with GLP-1 receptor agonist therapy and advise monitoring for NAION during eye examinations. The same guidance continues to recognize substantial metabolic and cardiovascular benefits of appropriate GLP-1-based treatment.
This is a useful reminder that medication decisions should be based on the individual’s benefit-risk balance, rather than on a single adverse-event signal in isolation.
GLP-1 and NAION: What should patients do now?
- Do not panic. NAION is very rare.
- Do not stop an effective GLP-1 medicine on your own.
- Know the warning symptoms. Sudden painless vision loss requires urgent assessment.
- Continue routine diabetic eye examinations when indicated.
- Tell your ophthalmologist about your diabetes and weight-loss medicines.
- Control vascular risk factors such as glucose, blood pressure, lipids and smoking.
- Discuss individual risk with your endocrinologist if you have previous optic-nerve disease or significant eye disease.
GLP-1 and NAION: Current Status in September 2026
| Question | Current status |
|---|---|
| Is NAION a recognized safety concern? | Yes, particularly for semaglutide. |
| Is NAION common? | No. It is very rare. |
| Is causality proven for the entire GLP-1 class? | No. |
| Do observational studies show an association? | Some do, while evidence remains heterogeneous. |
| Is the absolute risk large? | No. Available regulatory estimates indicate a very low absolute risk. |
| Is the same risk established for tirzepatide? | No. Current evidence is insufficient to establish the same signal. |
| What should sudden vision loss trigger? | Urgent ophthalmological assessment. |
GLP-1 medicines still have important benefits
It is important not to interpret the NAION signal without considering why these medicines are prescribed.
For appropriately selected patients, GLP-1-based therapies can substantially improve glycemic control and body weight. Depending on the specific medicine and clinical indication, they may also provide cardiovascular or kidney benefits.
For many patients, the relevant question is therefore not simply “Are GLP-1 medicines safe?” but rather “What are the benefits and risks of this treatment for me?”
This is particularly important in patients with type 2 diabetes, obesity, cardiovascular disease or chronic kidney disease, where effective metabolic treatment can have important long-term benefits.
GLP-1 treatment in Ahmedabad
If you are taking or considering semaglutide, tirzepatide or another GLP-1-based treatment for diabetes or obesity, treatment should be individualized according to your medical history, metabolic risk, eye health and treatment goals.
Dr. Moxit Shah, DM Endocrinologist, provides endocrinology-focused evaluation and management for diabetes, obesity, medical weight management and GLP-1-based therapies at Vishuddha Endocrine Clinic, Ahmedabad.
Vishuddha Endocrine Clinic
Elite Magnum, Bhuyangdev Cross Road, Memnagar/Ghatlodia, Ahmedabad
Phone: +91 99799 92797
Website: endocrinologistinahmedabad.com
Related Articles
- GLP-1 Medicines in 2026: Benefits, Weight Loss, Safety & Who May Benefit
- Traveling With GLP-1 Injections: Airport, Flight, Storage & Safety Guide
- GLP-1 for Weight Loss: What to Expect Month by Month
- GLP-1 and Alcohol: Can You Drink on Ozempic or Mounjaro?
References
- European Medicines Agency – NAION and semaglutide
- Diabetes Care 2026 – GLP-1 RAs and NAION
- ADA Standards of Care in Diabetes—2026
- UK MHRA – Semaglutide and NAION
- 2026 systematic review and meta-analysis of GLP-1 RAs and NAION
This article is for education and does not replace an individual medical consultation. Do not start, stop or change prescription medication without discussing it with your treating clinician. Sudden vision loss requires urgent medical assessment.
